

PRESS RELEASE

Basilea's Head of Global Human Resources, Heidi Mc Daid, to retire and Ursula Eberhardt named as successor

Basel, Switzerland, December 29, 2015 – Basilea Pharmaceutica Ltd. (SIX: BSLN) reports today that Heidi Mc Daid, Head of Global Human Resources and member of the management committee, will retire effective December 31, 2016.

Ronald Scott, Basilea's Chief Executive Officer, commented: "Heidi Mc Daid joined Basilea in 2002. In her 13 years with the company, she established and managed Basilea's Human Resources Department and provided valuable advice and support to Basilea as it has grown. We sincerely thank Heidi for her commitment and valuable contribution to Basilea's success throughout the years."

Ursula Eberhardt, currently Deputy Head of Basilea's Human Resources Department, will succeed Ms Mc Daid. Ms Eberhardt has been with Basilea for nine years and served as deputy head for the past six years.

Ronald Scott commented, "We are very pleased that Ms Eberhardt has accepted the position of Head of Basilea's Human Resources Department effective upon Ms Mc Daid's retirement. As Deputy Department Head, Ms Eberhardt will bring a wealth of experience to the position."

About Basilea

Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products that address increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. The company uses the integrated research, development and commercial operations of its subsidiary Basilea Pharmaceutica International Ltd. to discover, develop and commercialize innovative pharmaceutical products to meet the medical needs of patients with serious and potentially life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Media Relations	Investor Relations
Peer Nils Schröder, PhD Head Public Relations & Corporate Communications +41 61 606 1102 media_relations@basilea.com	Barbara Zink, PhD, MBA Head Corporate Development +41 61 606 1233 investor_relations@basilea.com

This press release can be downloaded from www.basilea.com.